Search
(S)-5-(7-(4-(4-Ethyl-4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole
go.drugbank.com/drugs/DB08725ExperimentalThese are aromatic compounds containing an ether group substituted with a benzene ring. This substance targets the protein genome polyprotein. … (S)-5-(7-(4-(4-Ethyl-4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole is a solid. This compound belongs to the phenol ethers.
Pimagedine
go.drugbank.com/drugs/DB05383InvestigationalIt is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies.
Vicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1.
Dicloxacillin
go.drugbank.com/drugs/DB00485ApprovedInvestigationalVet approvedOne of the penicillins which is resistant to penicillinase.
Products: DICLOXACILINA 250 MG POLVO PARA RECONSTITUIR A SUSPENSIÓN ORALTelithromycin
go.drugbank.com/drugs/DB00976ApprovedTelithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. … Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one.
D-JNKI-1
go.drugbank.com/drugs/DB05660InvestigationalA synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigational[L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … [A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19.
CRx-119
go.drugbank.com/drugs/DB05688ExperimentalCRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine. … CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of
Acetohexamide
go.drugbank.com/drugs/DB00414ApprovedWithdrawnA sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.